Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
The Technology Select Sector SPDR® Fund
XLK
4
Direxion Daily Energy Bull 2X Shares ETF
ERX
5
Invesco Solar ETF
TAN
CN Stock MarketDetailed Quotes
Betta Pharmaceuticals (300558)
- 48.83
- +0.12+0.25%
Market Closed May 20 15:00 CST
20.54BMarket Cap46.55P/E (TTM)
49.52High47.77Low86.64KlotVolume48.69Open48.71Prev Close420.95MTurnover2.07%Turnover Ratio67.26P/E (Static)420.73MShares79.8052wk High3.02P/B20.48BFloat Cap40.1052wk Low58.45Limit Up419.39MShs Float159.66Historical High38.97Limit Down3.59%Range %21.56Historical Low0.20Dividend TTM48.59Avg Price42.49KlotAsk0.41%Div Yield TTM100Lot Size38.77KlotBid
300558 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
300558 Orderflow
Unit: --
300558 Orderflow Trend
IntradayDayWeekMonth
No Data
Betta Pharmaceuticals (300558) News
We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings
Xcovery Partners With EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.
Medicine Chronicles ⑦: With over 70 billion yuan in revenue, how did China create a domestic "blockbuster drug"?
① The development of China's innovative pharmaceuticals sector has indeed been rapid. In addition to antibody drugs, cutting-edge fields such as cell and gene therapy, as well as small nucleic acid drugs, are also accelerating. Based on the number of early-stage research projects and clinical pipelines, China’s innovative pharmaceutical industry is continuously catching up with mature markets in Europe and the United States, with certain sub-sectors already able to rival them; ② The core logic by which the current market evaluates innovative drugs essentially remains expanding growth potential through overseas expansion.
Beta Pharma: First Quarter Report for 2026
Beta Pharma: 2025 Annual Report
Beta Pharma: Summary of the 2025 Annual Report
Betta Pharmaceuticals (300558) Stock Forum
Betta Pharmaceuticals' performance last year suggests unresolved challenges, worse than the annualized loss of 0.9% over the last half decade. This long-term share price weakness may be a bad sign, but contrarian investors might see it as a potential turnaround opportunity.
Betta Pharmaceuticals' (SZSE:300558) Earnings Have Declined Over Three Years, Contributing to Shareholders 62% LossThe high P/E ratio of Betta Pharmaceuticals Co., Ltd. can be attributed to anticipated strong growth and better performance than the market. Shareholders seem to be holding on to the stock, expecting a more prosperous future based on these prospects.
Analysts express uncertainty over Betta Pharmaceuticals' performance given the gap between company metrics and industry growth. Observations point to insignificance of benefits from reinvestments for investors due to low ROE and flat earnings growth.
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)